展商
展品
达泽优®
展商：Takeda Pharmaceutical Company Limited
原产国/地区：日本
目前全球唯一一款针对遗传性血管性水肿预防发作的单克隆抗体（mAb）药物，可降低患者的水肿反复发作次数，预防致命性喉头水肿所导致的窒息，填补了中国HAE长期无针对性治疗的空白。
展品详情
Takhzyro is the only plasma kallikrein inhibitor which indicated to the lPT standard care for HAE in China. It is an innovative and efficacious treatment which can reduce the potential risk of HAE attackes and improve the quality of life for patients with proven safety profile.